Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.

Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer

Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics Eyes Pivotal Trial Path After Encouraging Interim Results

Financial Comparison: Biodexa Pharmaceuticals (NASDAQ:BDRX) versus Radiopharm Theranostics (NASDAQ:RADX)

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Average Rating of “Buy” by Brokerages

Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages

RAD Increases Ownership in Radiopharm Ventures to 87.5%

Why Is Radiopharm Theranostics Stock Rallying Over 140%?

Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases